Post

AC Immune reports positive data from Alzheimer’s disease vaccine trial

At week six, the ACI-24.060 vaccine elicited an anti-Abeta antibody response in ABATE’s first, low dose cohort of AD patients.

FDA accepts Intercept’s resubmitted NDA for obeticholic acid

According to GlobalData’s Pharmaceutical Intelligence Center, obeticholic acid currently has a 64% likelihood of FDA approval.

Mapping endpoints: building gene therapy trials for the future

How can gene therapy trials choose the best endpoints to navigate development and demonstrate patient value?

Predictive analytics in drug development: state of play

From bypassing animal testing to forecasting outcomes, we review some of the latest use cases of predictive analytics in drug development.

Small Pharma’s depressive disorder therapy trial meets primary goal

The trial assessed the safety and efficacy of IV SPL026 with supportive therapy in 34 MDD patients.